Following the license agreement between TransferTech Sherbrooke and AmorChem to optimize molecules with antibiotic properties, the AmorChem venture capital fund announced on April 17, 2019 by press release its first investment in the project of Professors François Malouin and Éric Marsault of the Université de Sherbrooke.
“The agreement reached by TransferTech Sherbrooke with AmorChem and the financing of this major project will allow the research team led by Pr. François Malouin and Pr. Éric Marsault to work on the development of a new antibacterial compound. New efficacious antibiotics are crucial to the progress of modern medicine. We are therefore very happy to have contributed to the promotion of this innovative technology,” comments Michel Lambert, CEO of TransferTech Sherbrooke.
To read the press release: https://www.businesswire.com/news